Johnson & Johnson (NYSE ... is an approved treatment for schizophrenia and depression related to bipolar I or II disorder. It may also soon obtain approval for major depressive disorder.

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

On January 22, Johnson & Johnson released financial ... the FDA approved Spravato for the treatment of MDD [major depressive disorder], which affects about 21 million Americans, according to ...

CAPLYTA net product sales grew to $199.2 million, representing a 51%increase over the same period in 2023Full year 2024 ...

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator.

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...

In a remarkable display of market confidence, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) stock has reached an all-time high, touching a price level of $128.01. According to InvestingPro data, the ...

In a recent special meeting, Firefly Neuroscience, Inc. (NASDAQ:AIFF), a Delaware-based prepackaged software company with a market capitalization of $122.84 million, received stockholder approval for ...